skeletal muscle is the most abundant human tissue; therefore, an unlimited availability of myogenic cells has applications in regenerative medicine and drug development. Here we detail a protocol to derive myogenic cells from human embryonic stem (es) and induced pluripotent stem (ips) cells, and we also provide evidence for its extension to human ips cells cultured without feeder cells. the procedure, which does not require the generation of embryoid bodies or prospective cell isolation, entails four stages with different culture densities, media and surface coating. pluripotent stem cells are disaggregated to single cells and then differentiated into expandable cells resembling human mesoangioblasts. subsequently, transient Myod1 induction efficiently drives myogenic differentiation into multinucleated myotubes. cells derived from patients with muscular dystrophy and differentiated using this protocol have been genetically corrected, and they were proven to have therapeutic potential in dystrophic mice. thus, this platform has been demonstrated to be amenable to gene and cell therapy, and it could be extended to muscle tissue engineering and disease modeling.
IntroDuctIon
Skeletal muscle regenerates after injury or during chronic diseases such as muscular dystrophies. Muscular dystrophies are a heterogeneous group of disorders characterized by progressive muscle wasting that cause serious mobility and breathing impairment, leading to death in the most severe forms 1 . Regeneration relies mainly on adult stem cells called satellite cells 2 , which reside underneath basal lamina of the myofibers and generate committed progenitors called myoblasts.
At present, there is no definitive cure available for such diseases, although a number of experimental treatments are undergoing preclinical and clinical experimentation 2, 3 . Among these, cell therapy aims at providing a nonmutated copy of the gene of interest while restoring the lost tissue and (ideally) its stem or progenitor cell compartment. However, despite the promising results obtained in mouse models, clinical trials with myoblast transplantation in patients with muscular dystrophy indicate that their use might be restricted to local delivery 4 . Other myogenic cells can also be isolated from skeletal muscle 2 . Among them, pericyte-derived mesoangioblasts 5 are a promising population that can be delivered systemically; they have recently undergone clinical experimentation for Duchenne muscular dystrophy (DMD, OMIM no. 310200; EudraCT no. 2011-000176-33).
Although allogeneic cell therapy could be a feasible option, autologous transplantation would be desirable, as it would avoid or reduce immunosuppressive therapy for patients. However, the cycles of degeneration-regeneration of dystrophic muscle challenge the availability and proliferation potential of tissue-derived progenitors for autologous therapies [6] [7] [8] [9] [10] [11] . In addition, the largescale expansion required to generate adequate cell numbers for drug screening platforms and tissue engineering also challenges the proliferative potential of myogenic cells derived from adult muscle, posing a major hurdle for the development of successful therapeutic interventions. iPS cells could provide a solution to this limitation 12 . However, this requires the development and validation of safe and efficient methods to differentiate iPS cells toward specific cell lineages.
To overcome the above-mentioned limitations, we developed a protocol to differentiate human pluripotent stem cells into an expandable cell type similar to mesoangioblasts that efficiently generates skeletal muscle upon induction of the myogenesis regulator Myod1 (ref. 11) . We have demonstrated that these iPS cell-derived, patient-specific, myogenic cells can be genetically corrected, expanded in culture and differentiated into multinucleated myotubes in vitro, contributing to skeletal muscle regeneration by restoring the missing gene and protein upon transplantation in dystrophic animals 11, 13 . In addition, similarly to their tissuederived counterparts, human iPS cell-derived mesoangioblast-like cells also exert immunomodulatory effects on T cell proliferation 14 , a relevant finding for their possible use in cell therapies. Notably, when this protocol was used to differentiate mouse iPS cells, transplantation of the derived progeny resulted in the amelioration of muscle function of the treated dystrophic mice 11 .
In this paper we detail the experimental procedure that allows the derivation of mesoangioblast-like myogenic cells defined as HIDEMs (human iPS cell-derived mesoangioblast-like cells) from healthy and disease-specific human iPS cells. This is achieved via a stepwise differentiation process that consists of sequential monolayer cultures over 3 weeks. Pre-existing methods to generate vascular cells from human ES cells facilitated the initial setup of the protocol 15 . New evidence of extension of this procedure to human iPS cells cultured without feeder cells (feeder-free/FF HIDEMs) and to human ES cells (HEDEMs; human ES cell-derived mesoangioblast-like cells) is also provided. These cells are expandable in culture and nontumorigenic in vivo. Efficient myogenic
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the starting population of the protocol. Pluripotent cells need to be cultured under appropriate conditions, and they must not contain a substantial population of differentiated cells, which might compromise the success of the procedure. Adequate cell pluripotency needs to be assessed before the start of the procedure as a prerequisite for an effective outcome. This includes expression analysis of pluripotency genes (e.g., NANOG, POU5F1 (also known as OCT3/4), and KLF4) and in vitro and in vivo analysis of the differentiation potential 28 (e.g., teratoma formation assay).
Both feeder-dependent and feeder-free iPS cultures have been used with comparable results in terms of efficiency of differentiation; a few steps have been refined specifically for feederfree cultures. Although some feeder cells can contaminate the feeder-dependent cultures in the first steps of the derivation protocol, they are then rapidly lost owing to their mitotic inactivation and they have not been found in the final product. An overview of representative cell morphology at different steps is shown in Figure 2 .
In detail, feeder-dependent human iPS 11 and ES cells (Shef-6 cells 29 ) are cultured on a layer of mitomycin-treated mouse embryonic fibroblasts plated on Matrigel (iPS cells) or gelatin (ES cells) in KnockOut DMEM-based medium. For passaging, feederdependent pluripotent clones are detached with a solution of 1 mg/ml collagenase IV in KnockOut DMEM and then split 1:3-1:5. Feeder-free human iPS cells (System Biosciences, no. SC102A-1N; similar results have been obtained also with an additional line) are cultured in Essential 8 medium on a Geltrex matrix. For passaging, feeder-free cells are detached with 0.5 mM EDTA in PBS and subsequently passaged at a split ratio of 1:4-1:6.
The first stage of the protocol entails the disaggregation of pluripotent colonies to single cells. According to the results obtained across more than 20 different human pluripotent stem cell lines, this is the most crucial step of the protocol in terms of cell survival. Pretreatment of the cells with ROCK inhibitor 30 substantially decreases cell mortality in this step of the protocol. Cell populations that are particularly sensitive to single-cell disaggregation might yield suboptimal results at this step, and a higher input of pluripotent cell colonies might be necessary in order to obtain a satisfactory outcome. As a general rule, even if some cell death is present in the culture 1 d after single-cell passaging, as long as the cell-plating density is appropriate the results of the protocol will not be negatively affected. Culturing dissociated pluripotent cells on a Matrigel-coated surface exposes them to laminin, collagen IV, heparan sulfate proteoglycans and entactin/nidogen, all components of the vascular and skeletal muscle basement membranes 31 . Notably, Matrigel itself is known to promote vascular cell differentiation in vitro and in vivo in angiogenesis assays 32, 33 , as well as differentiation of myogenic cells 34 . Importantly, laminin and collagen IV, besides being the two main components of Matrigel, are produced by myoblasts and muscle fibroblasts and assembled on the surface of myotubes during differentiation 35 . They also represent the two main components of the extracellular matrix (ECM) of the muscle satellite stem cell niche 36 . Therefore, we hypothesized that exposure to the ECM molecules at both cell densities and in medium similar to that established for human ES differentiation into vascular smooth muscle cells 15 could prime pluripotent cells toward the mesodermal, vascular and myogenic lineages. Upon transferring the cultures into a medium optimized to culture human mesoangioblasts 37 , the cells are then maintained in a status that allows their in vitro expansion. Human ES/iPS cell-derived mesoangioblast-like cells will be referred from now on as HEDEMs and HIDEMs when derived from human ES or human iPS cells, respectively.
Expansion and cryopreservation of HEDEMs and HIDEMs (Steps 36-45).
HEDEMs and HIDEMs, the end products of this protocol, are cultured as skeletal muscle pericyte-derived mesoangioblasts 37 , and they have the advantage of a robust expansion potential (Fig. 3) before undergoing terminal differentiation, a key advantage over most tissue-derived adult progenitors. Cells are expanded on normal cell culture plastic without any LGMD2D HIDEMs (disease-/patient-specific)
DMD HIDEMs (disease-/patient-specific) HEDEMs (hES cell-derived) LGMD2D, limb girdle muscular dystrophy 2D; DMD, Duchenne muscular dystrophy. Please note that DMD HIDEMs were also genetically corrected with a human artificial chromosome containing the entire human dystrophin genetic locus (DYS-HAC) 11, 38 . Error bars show s.d. coating in a MegaCell-based medium supplemented with nutrients and basic fibroblast growth factor (bFGF; see Reagent Setup for a detailed medium composition). Alternatively, cells can also be grown using Iscove's modified Dulbecco's medium supplemented as described in Reagent Setup. Frozen stocks can be cryopreserved for short-term storage at −80 °C or in liquid nitrogen, where they remain viable for at least 4 years after freezing.
Characterization of HEDEMs and HIDEMs (Steps 46-68).
Specific assays are required to evaluate the quality of the derived HEDEM and HIDEM populations in terms of their immunophenotype and safety profile. Human ES and iPS cell differentiation with this protocol yields relatively homogeneous populations of mesoangioblast-like cells. For this reason, there is no prospective (e.g., FACS-based) isolation of specific cell populations in this protocol. However, a retrospective characterization of the cells is required to ensure that the desired cell population was obtained. This can be done by flow cytometry analysis once the culture is stabilized. Specifically, the markers routinely assessed are the following: CD13, CD31, CD56, CD44, CD45, CD49b, CD146, alkaline phosphatase (AP) and stage-specific embryonic marker 4 (SSEA4; Fig. 4 ). In brief, CD146 (a vascular/perivascular marker in vivo), CD13, CD44 and CD49b expression is usually high (above 50%). CD56 (myoblast marker), CD45 (panhematopoietic marker) and CD31 (endothelial cell marker) are very low or negative. AP detection via flow cytometry is not ideal, as the antibody limits its detection to the membrane isoform. For this reason, AP expression ranges from dim to very low. However, it is important to detect at least one of the two markers CD146 and AP. When AP signal is not detectable via flow cytometry, we advise that AP activity be detected via an enzymatic reaction ( Supplementary Fig. 1a and Supplementary Methods). SSEA4, a pluripotency-associated marker, should be negative or low. If cell preparations display more than 10% positivity for SSEA4, it is crucially important to perform analysis of residual retention of pluripotency by immunofluorescence analysis or quantitative real-time PCR (as shown in Tedesco et al. 11 ) and an in vivo tumorigenic assay. HIDEMs and human mesoangioblasts have also been shown to be positive for CD73 and CD105 (ref. 14), although we do not routinely assess the expression of these two markers in our studies. For representative results on HIDEMs, feeder-free HIDEMs and HEDEMs, please refer to Figure 4 .
Even though the assessment of surface markers by flow cytometry already provides indications of the possible presence of undifferentiated cells, it is good practice to assess HEDEMs and HIDEMs for any residual expression of pluripotency markers. This can be done using different techniques, such as immunofluorescence analysis (detailed in Steps 57-68 and shown in Supplementary Fig. 1b ) of OCT3/4, NANOG, SOX2 and KLF4 or quantitative real-time PCR (as shown in our previous paper 11 ) analysis of the genes that encode these transcription factors. HEDEMs/HIDEMs are expected to have very low or no expression of OCT3/4, NANOG, SOX2 and KLF4. All the analyses should be carried out by comparing the expression of the above genes and proteins in HEDEMs and HIDEMs versus the parental ES or iPS cell lines. It is also useful to test the expression of the exogenous pluripotency transgenes by quantitative real-time PCR when integrating vectors are used to establish the initial iPS cell population (as shown in Tedesco et al. 11 ). highlighted a remarkable similarity between them and skeletal muscle-derived mesoangioblasts 11 . However, the same analysis also revealed that, at variance with their tissue-derived counterpart, they did not express key genes of the myogenic program such as MYOD1 (see supplementary material in ref. 11). Indeed, HEDEMs and HIDEMs are not capable of spontaneous skeletal myogenesis, although their potential to fuse with myotubes can be triggered upon coculture with myogenic cells 11 . Moreover, previous work from our laboratory has shown that lentiviralmediated expression of Myod1 activates the myogenic program in mesoangioblasts without erasing their ability to cross the vessel wall upon intra-arterial delivery and to contribute to the satellite cell pool 38 .
Induction of myogenic differentiation via
Therefore, HIDEMs and HEDEMs were transduced with a lentiviral vector encoding Myod1 cDNA fused with the estrogen receptor (MyoD-ER(T) 39 ), thus allowing inducible nuclear translocation of the protein from the cytoplasm upon tamoxifen administration (in vitro and/or in vivo). By using this strategy, we have reproducibly observed very efficient myogenic differentiation, with an efficiency of up to 90% with only two 4-OH-tamoxifen pulses in vitro. Importantly, cells that have an integrated MyoD-ER(T) transgene but that are not exposed to tamoxifen (i.e., having an inactive Myod1 cytoplasmic protein) retain a good proliferation capacity, although moderately reduced compared with the parental cell line, and they can be expanded in culture (Fig. 3) . Upon tamoxifen administration, MyoD-ER(T) HEDEMs and HIDEMs undergo robust and synchronous myogenic differentiation. Evaluation of the expression of myogenic differentiation markers such as myosin heavy chain (MyHC) by immunofluorescence staining allows assessing the differentiation efficiency as the percentage of nuclei inside MyHC-positive cells versus the total number of nuclei (Fig. 5) . Notably, the possible future use of tamoxifen in vivo in cell therapy protocols based upon HIDEMs or MyoD-ER(T) could also be facilitated by its beneficial effect as a drug for DMD 40 . 41, 42 , screening the preclinical safety profile of ES-or iPS-derived cells is particularly relevant. Such an analysis must include an assay that checks that the medicinal product does not harbor tumorigenic properties. Before such a test, quality controls to evaluate the genome stability of the HEDEM or HIDEM cell lines are also advisable. These quality controls should be performed after completion of the commitment protocol. This can be done by karyotype analysis 11 or by means of novel technologies such as array comparative genomic hybridization 43 .
Checking the safety profile of pluripotent stem cell-derived myogenic cells (Steps 94-101). Now that iPS cells have entered clinical experimentation
To assess the risk of in vivo tumorigenesis, HEDEMs and HIDEMs are injected subcutaneously in immunodeficient animals. It is advisable to use a minimum of five immunodeficient mice and a consistent positive control (e.g., HeLa cells) for each cell population tested. This assay should only be performed for cell lines that provided satisfactory results during derivation and differentiation. Please note that all the work must be carried out under an appropriate animal license, and the guidelines for tumorigenic assays might vary between different regulatory institutions. We advise following the 'Guidelines for the welfare and use of animals in cancer research' 44 . As this is an assay based on a xenogeneic transplant, it is normally carried out over a period of at least 4 months, during which time animals are examined at least once a week. If the assay is negative (i.e., no tumor formation), the cell line can be considered safe for in vivo applications. Overall, we have tested nine human pluripotent stem cell-derived cell lines in vivo, and no tumor formation was observed (follow-up ≥4 months). Importantly, we have also compared HEDEMs (that are by definition transgene free) and MyoD-ER(T)-HEDEMs, which only contain the integrated MyoD-ER(T) to exclude any possible transformation event owing to insertional mutagenesis. We observed no tumor formation in either condition.
Level of expertise needed to implement the protocol
The minimum skills required to implement this protocol include cell culture experience with human pluripotent, adherent and myogenic cells. We advise outsourcing the production of the MyoD-ER(T) lentiviral vector if viral production is a technique not fully mastered in your laboratory. For the characterization of the final product (HEDEMs and HIDEMs), familiarity with basic fluorescence microscopy and with FACS analyses is required. For the in vivo tumorigenic assay, approval of a specific animal license needs to be in place before starting the procedure. Assessment of the regenerative potential can be performed by the transplantation of the final cell product in mouse models of muscle regeneration, as we recently detailed in a specific video protocol 13 .
Limitations of the protocol
Despite the high efficiency and reproducibility of our protocol in generating myogenic cells from human pluripotent cells, there might be some limitations to its use. First, to induce myogenic differentiation, we use an integrating lentiviral vector harboring a cassette encoding for MyoD-ER(T). On the basis of previously published transplantation experiments in immunocompetent dystrophic mice using the same MyoD-ER(T) construct 39 , we do not have reason to believe that the resulting fusion protein could be immunogenic for the host. However, further immunological studies to address this issue might be necessary before translating this technology to the clinic. Although integrating vectors that overexpress myogenic factors in pluripotent or progenitor cells have been used in other published protocols (e.g., Darabi et al. 20 ), safety concerns could arise owing to their integrating nature. However, the potential risk of insertional oncogenesis has been drastically reduced with third-generation self-inactivating lentiviral vectors 45 , which so far show an excellent clinical safety profile 46, 47 . Nevertheless, the risk of insertional mutagenesis must not be underestimated. It is possible to screen transgene insertion with ad hoc vector integration analyses, leading to the identification of clones with so-called 'safe harbor' integrations 46 . As an alternative strategy, we are currently investigating the use of integration-free platforms such as integration-deficient lentiviral vectors 48, 49 , human artificial chromosomes 50, 51 , or MyoD-mRNAs (commercially available, Stemgent cat. no. 05-0029).
Another potential limitation is that this method generates muscle cells without necessarily recapitulating skeletal muscle development in the embryo. Hence, the application of this protocol might not be suitable for research on specific developmental aspects of skeletal myogenesis. Nevertheless, it does provide an attractive platform to further fine-tune myogenesis and to possibly identify unknown factors that influence myogenic differentiation.
Finally, although this aspect is not of primary importance for drug screening platforms (in which the efficiency of differentiation is likely to be one of the key eligibility criteria for a protocol), a complete chemically defined, animal component-and transgene-free protocol is desirable. Thus, future upgrades of this methodology will focus toward this end, for example by replacing Matrigel and avoiding the use of integrating viral vectors. 
MaterIals

REAGENTS
Immunodeficient adult mice (e.g., scid/beige, NOD or NSG strains) from an authorized facility and kept in a specific pathogen-free environment ! cautIon Any experiment involving animal work must be carried out in accordance with specific regulations that vary across countries and institutions. Once the authorization for animal work is granted, we advise researchers to follow the 'Guidelines for the welfare and use of animals in cancer research' 43 
ROCK inhibitor Y27362
Resuspend the powder at a final concentration of 1 mg/ml. Divide the solution into aliquots and store them at −20 °C for up to 6 months. Use this reagent diluted to a 1:300 ratio in medium. Matrigel Thaw the stock solution overnight on ice at 4 °C, and once it is in liquid form keep it on ice and divide the solution into aliquots using cold tips and cold tubes. Store the solution at −20 °C according to product expiry date. When needed, thaw it on ice, dilute the solution to a 1:100 ratio in DMEM and use it the same day. Geltrex Thaw the stock solution overnight on ice at 4 °C, and once it is in liquid form keep it on ice and divide the solution into aliquots using cold tips and cold tubes. Store the solution at −20 °C for up to 18 months. When needed, thaw the solution on ice, dilute it to a 1:100 ratio in DMEM F12 DMEM and use it the same day. Iron sulfate Stock solution is provided at a concentration of 12.5 mg/ml (wt/vol). Dilute the solution to a ratio of 1:1,000 in sterile water and store it at 4 °C for up to 6 months. Use 530 µl/liter. Sodium ferric gluconate Stock solution is provided at a concentration of 25 mg/ml (wt/vol). Dilute the solution to a 1:1,000 ratio in sterile water and store it at 4 °C for up to 6 months. Use 3.3 ml/liter. Oleic acid Prepare a stock solution by dissolving the powder in sterile water at a concentration of 23.5 mg/ml (wt/vol), which is equal to 2.5 mM. Divide the solution into aliquots and store them at −20 °C for up to 6 months. Use the solution at a final concentration of 0.5 µM in medium. Linoleic acid Prepare a stock solution by dissolving the powder in sterile water at a concentration of 23 mg/ml (wt/vol), which is equal to 2.5 mM. Divide the solution into aliquots, and store them at −20 °C for up to 6 months. Use the solution at a final concentration of 0.5 µM in medium.
• 
2|
To increase single-cell survival after dissociation, pretreat the cells with 10 µM ROCK inhibitor by adding it to the cell culture medium. Incubate the mixture for 1 h at 37 °C.
3| Prepare a 35-mm dish coated with 1% (vol/vol) growth factor-reduced Matrigel, as described in Equipment Setup.
4|
Remove the medium with ROCK inhibitor from the plates, and then gently wash the cells with 2 ml of Ca 2+ -and Mg 2+ -free PBS.
5| Add 1 ml of prewarmed dissociation medium to each ES or iPS cell well; incubate at 37 °C for 10 min.
6| Shake the plates gently by tapping on their side to facilitate the dissociation of colonies. Inspect the plates and look for floating cells. If you are using feeder-dependent cultures, aim to detach most of the colonies at the expense of feeder cells, which will remain attached to the plastic. The first incubation is usually insufficient to detach all the cells, so put the plates back in the incubator and repeat this step every 15 min for up to 2 h. Move to the next step when most of the colonies detached as single cells or little clumps. iPS cells cultured in feeder-free conditions detach very easily from the dish, usually after 15 min of incubation at 37 °C. No further incubation should be required.  crItIcal step Do not keep the cells in dissociation medium for more than 2 h in total, as this decreases cell survival and compromises the following steps of the protocol.
7|
Collect the dissociation medium with the detached cells in a 15-ml sterile tube. Gently resuspend the cells with a P1000 pipette tip to facilitate the disaggregation of clumps.  crItIcal step For feeder-dependent cultures, make sure not to scrape the bottom of the dish so as not to detach feeder cells.
8|
Add at least 1 volume of prewarmed commitment medium to the tubes to dilute the dissociation medium.
9|
Centrifuge the cell suspension at 232g at RT for 5 min. 13| Replace commitment medium the next day to eliminate dead cells. Inspect the plate daily, and replace commitment medium every 2-3 d with prewarmed fresh commitment medium. See Figure 2 for representative cell morphology at this step. Move to the following step after 1 week.
14|
Intermediate commitment and adaptation to a reduced cell density. Prepare a 35-mm dish coated with 1% (vol/vol) growth factor-reduced Matrigel, as described in Equipment Setup.
15| Dissociate the cell culture from
Step 13 with prewarmed dissociation medium, as detailed in Steps 4-6. Additional gentle scraping of the dish surface can be performed if cells do not detach completely after a maximum of 2 h in dissociation medium. ? troublesHootInG 16| Collect the cells in dissociation medium in a 15-ml tube, and gently resuspend them with a P1000 pipette tip. Add 1 volume of prewarmed commitment medium.
17|
Filter the cell suspension with a 40-µm cell strainer placed on a collection tube in order to remove aggregates.
18|
Centrifuge the filtered cell suspension at 232g for 5 min at RT.
19|
Discard the supernatant, resuspend the pellet in prewarmed commitment medium and count the cells.  crItIcal step In order to plate the appropriate number of cells, it is important to evaluate the cell viability through a vital staining, such as trypan blue.
20| Wash the Matrigel-coated dish twice with DMEM or PBS, and plate 2.5 × 10 4 cells per cm 2 (~2 × 10 5 cells for a 35-mm dish).
? troublesHootInG
21|
Incubate the cells at 37 °C with 5% CO 2 and 3-5% O 2 .
22| Inspect the plate daily and replace the commitment medium every other day with fresh prewarmed medium. See Figure 2 for representative cell morphology at this step. Move to the next step after 1 week. ? troublesHootInG
23|
Late commitment: high-density culture and adaptation to trypsin dissociation. Prepare a 35-mm dish coated with 1% (vol/vol) growth factor-reduced Matrigel, as described in Equipment Setup.
24|
Wash the plate with the cells with 2 ml of PBS, and then add 0.5 ml of trypsin to detach them. Incubate the plates at 37 °C with 5% CO 2 and 3-5% O 2 for 5 min.
25|
Remove cells from the incubator and shake the plate to facilitate cell detachment. Inspect the plate under a microscope. When all the cells have detached, block trypsin activity with prewarmed commitment medium. Resuspend with a pipette and collect the cell suspension.
26|
Centrifuge the cell suspension at 232g for 5 min at RT.
27|
Discard the supernatant, resuspend the pellet in prewarmed proliferation medium and count the cells.  crItIcal step To plate the appropriate number of cells, it is important to evaluate cell viability through a vital staining, such as staining with trypan blue.
28|
Wash the Matrigel-coated dish twice with DMEM or PBS, and plate 2 × 10 4 cells per cm 2 (~1.6 × 10 5 cells for a 35-mm dish or at a confluence of 80%).
29|
Incubate the cells at 37 °C with 5% CO 2 and 3-5% O 2 . Inspect the cells daily and replace the medium every other day. See Figure 2 for representative cell morphology at this step. Move to the next step after 3 d at 100% confluence.
30| HEDEM and HIDEM culture stabilization. Detach the cells by trypsinization, as described in Steps 24 and 25.
31| Centrifuge the cell suspension at 232g for 5 min at RT.
32|
Discard the supernatant, resuspend the pellet in prewarmed proliferation medium and count the cells.
33| Plate 1.2 × 10 4 cells per cm 2 on cell culture plastic without any coating.
34|
35| Inspect the cells daily and split the culture by trypsinization as they reach 80% confluence. Different lines differ with respect to proliferation rate, but generally cultures require splitting every 3-4 d. The cell population at this step is regarded as HEDEM/HIDEM passage zero (p0). From now onward, cells are cultured similarly to bona fide mesoangioblasts 36 . The cells can now be expanded and cryopreserved. See Figure 2 for representative cell morphology at this step.
expansion and cryopreservation of HeDeMs/HIDeMs • tIMInG at least 7-10 d 36| HEDEM and HIDEM cultures require splitting when the culture is roughly 80% confluent. On the day of splitting, wash the plates once with PBS, add the volume of trypsin necessary to cover the whole culture surface, and incubate the cells at 37 °C for 5 min.
37| Shake the plate to facilitate cell detachment and inspect the cells under the microscope. When all the cells are detached, add prewarmed proliferation medium to block trypsin activity. Resuspend and collect the cells in a tube for centrifugation.
38|
39| Discard the supernatant, resuspend the pellet in prewarmed proliferation medium and count the cells. Plate 1.2 × 10 4 cells per cm 2 . Cells generally require a splitting ratio of 1:3-1:6 depending on the cell line.  crItIcal step From p0, HEDEMs and HIDEMs can be cryopreserved. It is highly recommended to cryopreserve a stock of cells at low passages (p0-3) and, if possible, it is good practice to freeze one vial of cells (or more) at each passage.
40|
Fill the lower chamber of a Nalgene freezing container with isopropanol, and then prechill the container at 4 °C.
41|
When cell culture reaches 80% confluency, detach the cells as detailed in Steps 36-38.
42|
Discard the supernatant and any residual medium left in the tube.
43| Disrupt the cell pellet by gentle tapping at the bottom of the tube.
44|
Resuspend the pellet in 1 ml of cold freezing medium, transfer it to a labeled cryovial and immediately put the vial in a freezing container. 
48|
Filter the cells through a 40-µm (pore size) cell strainer and count them.
49|
Place appropriate cell numbers in single centrifuge-proof FACS tubes. Usually, at least 1 × 10 5 cells are used for each antibody staining and for unstained controls.
50|
Centrifuge the tubes at 232g for 5 min at RT.
51|
Discard the supernatant, gently resuspend the pellet in 2 ml of FACS buffer for a wash and centrifuge at 232g for 5 min at RT.
52|
Discard the supernatant and gently tap the cell pellet to resuspend it in 50 µl of FACS buffer in the tube.
53|
Leave unstained control tubes on ice and set them aside until FACS read. In parallel, add staining antibodies to samples at the dilution described in the Reagents section (and table 1), and incubate them at 4 °C in the dark for 45 min. 
61|
Remove the permeabilizing solution, and incubate the cells with 10% (vol/vol) animal serum for 30 min at RT to block nonspecific binding sites.
62|
Remove the animal serum and incubate one dish with anti-Sox2, one with anti-Oct4 and one with anti-Nanog primary antibody for 1 h at RT.  crItIcal step We advise using the remaining dish to assess potential nonspecific binding of the secondary antibody to the sample and to evaluate an eventual level of background. This can be done by incubating the culture dish with only secondary antibody and nuclear dye (without primary antibody).
63| Perform three washes of 5 min with PBS/0.2% (vol/vol) Triton X-100 to remove unbound antibody.
64|
Incubate the dish with the appropriate secondary antibody conjugated with a fluorochrome of choice diluted in PBS/0.2% (vol/vol) Triton X-100/1% (wt/vol) BSA at RT for 1 h. In the same incubation, also counterstain the nuclei with a nuclear dye such as Hoechst.
65|
Perform two washes of 5 min with PBS/0.2% (vol/vol) Triton X-100 to remove unbound antibody, and one wash of 5 min with PBS.
66|
Carefully aspirate the last PBS wash from the dish, and then add one drop of fluorescence mounting medium.
67|
Put a coverslip on top of the dish to protect the specimen and prevent evaporation.
68|
Image the cells under a fluorescence microscope equipped with filters for the nuclear dye and the secondary antibody of choice. The following formula can be used for this purpose: µl of virus needed = number of cells to infect × desired MOI/number of cells to infect × desired MOI. ! cautIon Work involving the use of viral vectors must be carried out under a Class 2 biosafety cabinet. Appropriately inactivate any residual lentiviral vector particles on surfaces and liquids that were in contact with it before their disposal.  crItIcal step Titrate the MOI to find the amount of lentiviral vector that allows the cell culture to differentiate in MyHC-positive myotubes with an efficiency >50%. Differentiation efficiency can be assessed only after transduction. We suggest performing experiments with the cells that have the highest differentiation efficiency-to-MOI rate (i.e., the best differentiation with the lowest amount of lentiviral vector).
Induction of myogenic differentiation via
71|
Dilute the lentiviral vector in 1 ml of proliferation medium supplemented with 1 µl of Polybrene.
72|
Remove the medium from the 35-mm dish of MyoD-ER(T) HEDEMs or HIDEMs and replace it with the 1 ml of viral suspension. Incubate the cells for 12 h at 37 °C with 5% CO 2 and 3-5% O 2 .
73| Remove the medium and wash the plate twice with PBS. Put fresh proliferation medium on cells.
74|
Incubate the cells at 37 °C with 5% CO 2 and 3-5% O 2 and inspect them daily. 78| Incubate the cells in growth medium at 37 °C with 5% CO 2 and 3-5% O 2 .
75|
79| Check the cells daily and add 1 mM 4-OH tamoxifen to the proliferation medium when the cells reach 90-100% confluence.
80| After 24 h, replace the proliferation medium with fresh differentiation medium supplemented with 1 mM 4-OH-Tamoxifen.
81|
Inspect the cultures daily for myotube formation. Replace half of the differentiation medium daily. Myotubes are usually identifiable in culture starting from 3 d after the first tamoxifen addition.  crItIcal step Differentiated cultures are delicate, as myotubes detach easily when the plates are not handled gently. Medium change should be done slowly, and the medium should be added drop by drop on the side wall of the plate. 82| 6-7 d after the second tamoxifen administration and the switch to differentiation medium, the cell culture should be predominantly composed of multinucleated myotubes. These cultures are now ready to be analyzed. Wash the differentiated plate gently with PBS twice, and then fix it with 4% (wt/vol) paraformaldehyde for 10 min at RT. ! cautIon Paraformaldehyde is extremely toxic, and it must be handled under a chemical cabinet.  pause poInt Fixed cells can be kept with PBS at 4 °C for at least 2 weeks before proceeding with the staining.
83|
Permeabilize an aliquot of cells with PBS/0.2% (vol/vol) Triton X-100/1% (wt/vol) BSA for 30 min at RT.
84|
Remove the permeabilizing solution, and incubate the cells with 10% (vol/vol) animal serum for 30 min at RT to block the nonspecific binding sites.
85|
Remove the animal serum and incubate the dish with anti-MyHC primary antibody for 1 h at RT.  crItIcal step Another differentiated dish or a sector of the same dish needs be incubated with secondary antibody and nuclear dye alone; it is used to assess the eventual nonspecific binding of the secondary antibody to the sample and to evaluate the eventual level of background.
86| Perform three washes of 5 min with PBS/0.2% (vol/vol) Triton X-100 to remove unbound antibody.
87|
Incubate the dish with any anti-mouse secondary antibody conjugated with a fluorochrome of choice diluted 1:500 in PBS/0.2% (vol/vol) Triton X-100/1% (wt/vol) BSA at RT for 1 h. In the same incubation, also counterstain the nuclei with a nuclear dye such as Hoechst (1:250).
88|
Perform two washes of 5 min with PBS/0.2% (vol/vol) Triton to remove unbound antibody, and one wash of 5 min with PBS.
89|
Carefully aspirate the last PBS wash from the dish and add one drop of fluorescence mounting medium.
90|
Put a coverslip on top of the dish to protect the specimen and to avoid evaporation.
91|
Image the cells with a fluorescence microscope equipped with filters for the nuclear dye and the secondary antibody of choice. Take at least 10 random field pictures of the stained dish, using a microscope equipped with a 20× magnification lens (total magnification 200×).
92|
Merge nuclear dye images with MyHC images and count the total number of nuclei. Next, count only the number of nuclei localized within MyHC-positive myotubes.
93| Apply the following formula to obtain the differentiation efficiency percentage:
Number of nuclei within MyHC-positive myotubes × 100/total number of nuclei of the field.
checking the safety profile of pluripotent stem cell-derived myogenic cells • tIMInG 2 h for cell injection; at least 4 months follow-up  crItIcal This should be done with a fraction of the cultured cells.
94|
Detach the cells by trypsinization, as described in Steps 36-38.
95|
Discard the supernatant, resuspend the cell pellet by tapping at the bottom of the tube and resuspend it in at least 10 ml of PBS.
96|
97|
Discard the supernatant and resuspend the pellet in PBS to a final concentration of 2 × 10 6 cells per 150 µl (the volume of each injection).
98|
Bring the cells to the room designated for animal work, and prepare the mice for the procedure according to your animal license.  crItIcal step Ethical approval must be obtained for all animal work, and experiments need to be carried out in accordance with the animal regulations of your country and institution.
99| Inject 150 µl of the cell suspension subcutaneously in the back or in the dorsal flank of the immunodeficient mice (e.g., scid/beige, NOD or NSG strains). HeLa cells can be used as a positive control for tumor formation.
100|
Screen the animals twice per week for the presence of growing subcutaneous masses. A minimum follow-up (followed by necropsy) of 4 months is highly recommended.  crItIcal step Monitor the mice closely for clinical signs associated with tumor growth necessitating immediate culling (e.g., cachexia, dehydration, ulceration, pain and infection).
101|
If you observe tumor mass formation of >10 mm in diameter, humanely kill the animal to avoid causing pain or significant discomfort.
? troublesHootInG Troubleshooting advice can be found in table 2. 
antIcIpateD results
The protocol described here enables the efficient derivation of expandable mesoangioblast-like cells from both human ES and iPS cells (HEDEMs and HIDEMs, respectively) that can subsequently be easily differentiated into skeletal muscle cells (see Fig. 1 for a schematic overview of the entire method). The derivation of HEDEMs and HIDEMs entails different steps, from pluripotent colonies to single cells resembling mesoangioblasts, which can be expanded before or after transduction with a tamoxifen-regulated MyoD-ER(T) cassette. (Fig. 3) . A decreased proliferation rate might be observed upon MyoD-ER(T) transduction, but MyoD-ER(T) HEDEMs and HIDEMs are still capable of a substantial expansion. This expansion potential supports the theoretical feasibility of translating this iPS cell-based approach to possible clinical settings, in which several billion cells per patient might be required and where cell availability and expansion are often major bottlenecks. We observed a slight decrease in proliferation of feeder-free HIDEMs compared with feeder-dependent HIDEMs derived from the same iPS cell colonies. However, fewer lines were tested in comparison with feeder-dependent cultures; therefore, this observation might be related to variability normally existing among different cell lines. Nonetheless, possible issues of reduced proliferation could always be overcome by increasing the amount of colonies in the starting iPS cell populations.
HEDEMs and HIDEMs express surface markers that can be assessed by FACS, as shown in Figure 4 . In detail, HEDEMs and HIDEMs express CD146 (a perivascular marker), CD13, CD49b and CD44. AP, which is a marker of a subpopulation of skeletal muscle pericytes, shows variable expression levels among different cell lines. In addition, it is possible to evaluate more accurately AP activity via enzymatic reaction, as shown and described in supplementary Figure 1a . Notably, even though some cell lines express low AP levels, this does not affect the quality of the final product, provided that other markers (e.g., CD146, CD13, CD44 and CD49b) and parameters (e.g., in vitro differentiation assays) are met. Cells have to be negative or only weakly positive for CD56, SSEA4 and CD31. Representative percentages of positivity for all the different markers quoted above are shown in supplementary table 1. Furthermore, HEDEMs and HIDEMs do not display any marked residual expression of pluripotency-associated markers, and this can be easily detected by an immunofluorescence analysis for Sox2, Nanog and Oct4 expression (supplementary Fig. 1b) .
Once HEDEMs or HIDEMs have been characterized for their surface markers, they can be differentiated into multinucleated skeletal myotubes. To this aim, the use of a tamoxifen-regulated Myod1 vector (MyoD-ER(T)) synchronizes the differentiation of the whole culture. To obtain optimal results in terms of both cell proliferation and skeletal muscle differentiation, it is a good practice to titrate the MOI of the MyoD-ER(T) lentiviral vector for every newly generated line. You should aim for a differentiation efficiency of at least 50% of the total population (although we have observed differentiation efficiency >90% with lines infected with a MOI <5). Representative images of differentiated HEDEM and HIDEM lines can be found in Figure 5 . The differentiation efficiency of each line is calculated by counting the number of nuclei inside MyHC-positive cells over the total number of nuclei in at least ten randomly selected fields of the differentiated dishes (20× magnification; supplementary table 2). The ratio, expressed as percentage, is an index of the differentiation efficiency of the examined cell line. We have also incidentally observed the formation of sarcomeric striations and spontaneous twitching of myotubes derived from HIDEMs after 8 d in myogenic differentiation medium (supplementary Video 1). However, as this is not observed frequently, we do not rely on these parameters to monitor the efficiency of the protocol, which indeed is best achieved by using MyHC immunofluorescence staining.
Tumorigenic assays and transplantation experiments of HEDEMs and HIDEMs in immunodeficient mice demonstrate that the procedure is safe. For all the cell lines tested, no tumors were found after a minimum of 4 months of follow-up. Assessment of the regenerative potential of the final product is then performed by cell transplantation in mouse models of muscle regeneration, as recently detailed in a specific video protocol 13 . In the version of this article initially published, the concentration of ROCK inhibitor Y27362 in Step 2 was incorrectly given as 10 mM. The correct concentration to be used is 10 μM. The error has been corrected in the HTML and PDF versions of the article.
